Published in Stat Med on August 01, 1993
Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer (2013) 1.50
Sample size: how many patients are necessary? Br J Cancer (1995) 1.15
Evaluation of a predevelopment service delivery intervention: an application to improve clinical handovers. BMJ Qual Saf (2012) 0.83
A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials. Contemp Clin Trials (2013) 0.79
A Quantitative Process for Enhancing End of Phase 2 Decisions. Stat Biopharm Res (2014) 0.76
Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurol (2015) 0.76
CORR Insights(®): Prediction of Postoperative Clinical Recovery of Drop Foot Attributable to Lumbar Degenerative Diseases, via a Bayesian Network. Clin Orthop Relat Res (2017) 0.75
Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure. Trials (2017) 0.75
Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial. Trials (2016) 0.75
The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis. Bone Joint Res (2017) 0.75
Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol (2001) 11.17
Meta-analysis of the literature or of individual patient data: is there a difference? Lancet (1993) 6.16
Breast cancer clusters in the northeast United States: a geographic analysis. Am J Epidemiol (1997) 5.73
Tables of the number of patients required in clinical trials using the logrank test. Stat Med (1983) 5.34
Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer (1978) 5.25
On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics (1976) 3.82
Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res (1978) 3.51
Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst (1996) 2.98
Implications of a new dietary measurement error model for estimation of relative risk: application to four calibration studies. Am J Epidemiol (1999) 2.40
Empirical evidence of correlated biases in dietary assessment instruments and its implications. Am J Epidemiol (2001) 2.33
Injuries sustained on "bouncy castles". BMJ (1992) 2.20
Randomised consent designs in cancer clinical trials. Eur J Cancer (1995) 2.07
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer (1979) 1.92
The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. Stat Med (1994) 1.90
Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. J Natl Cancer Inst (1995) 1.84
A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Stat Med (1986) 1.82
Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet (1987) 1.79
Is double data entry necessary? The CHART trials. CHART Steering Committee. Continuous, Hyperfractionated, Accelerated Radiotherapy. Control Clin Trials (1994) 1.64
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63
Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst (1994) 1.61
Can energy adjustment separate the effects of energy from those of specific macronutrients? Am J Epidemiol (1994) 1.56
Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer (1991) 1.49
The use of a Kolmogorov--Smirnov type statistic in testing hypotheses about seasonal variation. J Epidemiol Community Health (1979) 1.49
Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer (1995) 1.41
Bayesian monitoring of phase II trials in cancer chemoprevention. J Clin Epidemiol (1999) 1.41
A stratified Wilcoxon-type test for trend. Stat Med (1990) 1.40
The future of prognostic factors in outcome prediction for patients with cancer. Cancer (1992) 1.39
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) (1988) 1.39
Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) (1997) 1.38
Stopping rules for clinical trials incorporating clinical opinion. Biometrics (1984) 1.33
Effect of starvation on the tissue composition of the small intestine in the rat. Am J Physiol (1968) 1.31
Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement? Lancet (1979) 1.29
Variations in the level of reporting by hospitals to a regional cancer registry. Br J Cancer (1978) 1.29
Randomized, placebo-controlled, double-blind study of low-dose oral interferon-alpha in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr (1992) 1.27
An assay for dopamine-beta-hydroxylase activity in tissues and serum. Experientia (1971) 1.26
Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer (1996) 1.22
Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med (1997) 1.21
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer (1998) 1.19
Multivariate analysis of prognostic factors for operable rectal cancer. Lancet (1984) 1.18
The what, why and how of Bayesian clinical trials monitoring. Stat Med (1994) 1.16
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev (1996) 1.15
Monitoring clinical trials: conditional or predictive power? Control Clin Trials (1986) 1.14
Interplay between design and analysis for behavioral intervention trials with community as the unit of randomization. Am J Epidemiol (1995) 1.13
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13
Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Res (1997) 1.11
An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10
A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys (2000) 1.10
System delay in breast cancer in whites and blacks. Am J Epidemiol (1995) 1.09
Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ (1994) 1.09
Validation of intermediate end points in cancer research. J Natl Cancer Inst (1990) 1.07
Serum dopamine-beta-hydroxylase activity in neuroblastoma. N Engl J Med (1972) 1.05
Improving the quality of data in randomized clinical trials: the COMPACT computer package. COMPACT Steering Committee. Stat Med (1988) 1.03
A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol (1978) 1.02
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
Interpretation of biopsies of "normal" urothelium in patients with superficial bladder cancer. MRC Superficial Bladder Cancer Sub Group. Br J Urol (1991) 0.99
Checking for completeness of 24-h urine collection using para-amino benzoic acid not necessary in the Observing Protein and Energy Nutrition study. Eur J Clin Nutr (2013) 0.99
Energy adjustment methods for nutritional epidemiology: the effect of categorization. Am J Epidemiol (1994) 0.99
Interpretation of energy adjustment models for nutritional epidemiology. Am J Epidemiol (1993) 0.99
Changes in human serum dopamine- -hydroxylase activity with age. Nature (1972) 0.98
Sample size calculation for clinical trials: the impact of clinician beliefs. Br J Cancer (2000) 0.98
Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys (1998) 0.98
Bayesian design and analysis of two x two factorial clinical trials. Biometrics (1997) 0.98
Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer (1998) 0.97
Limitations of mortality data as a guide to comparative lung cancer incidence within an urban area. Public Health (1979) 0.97
Conditional logistic regression with sandwich estimators: application to a meta-analysis. Biometrics (1998) 0.97
Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant (2010) 0.97
Bias in the analysis and reporting of randomized controlled trials. Int J Technol Assess Health Care (1996) 0.96
Measurement error and dietary intake. Adv Exp Med Biol (1998) 0.96
Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur Respir J (1997) 0.94
A unified method for monitoring and analysing controlled trials. Stat Med (1994) 0.93
Effect of measurement error on energy-adjustment models in nutritional epidemiology. Am J Epidemiol (1997) 0.92
Dopamine- -hydroxylase activity in mouse neuroblastoma tumors and in cell cultures. Proc Natl Acad Sci U S A (1972) 0.92
A modified approach to estimating sample size for simple logistic regression with one continuous covariate. Stat Med (2010) 0.92
Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol (2001) 0.91
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene (2009) 0.90
Early stopping of prevention trials when multiple outcomes are of interest: a discussion. Stat Med (1994) 0.90
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer (1996) 0.90
A radioimmunoassay of human circulatory dopamine-beta-hydroxylase. Life Sci (1973) 0.89
The impact of stopping rules on heterogeneity of results in overviews of clinical trials. Biometrics (1992) 0.89
The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments. Br J Cancer Suppl (1980) 0.89
Serum dopamine-beta-hydroxylase levels in Down's syndrome. Clin Genet (1974) 0.89
Traumeel S in preventing and treating mucositis in young patients undergoing SCT: a report of the Children's Oncology Group. Bone Marrow Transplant (2012) 0.88
Spontaneous regression of a desmoid tumour. J Bone Joint Surg Br (1986) 0.88
A familial study in serum dopamine-beta-hydroxylase levels in torsion dystonia. Neurology (1974) 0.88
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol (2013) 0.87
Diet and colorectal cancer: still an open question. J Natl Cancer Inst (1995) 0.87
Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol (2003) 0.87
Pathology review in cancer research. Br J Cancer (1993) 0.87
Seasonal variations in the clinical of presentation of Crohn's disease and ulcerative colitis. Int J Epidemiol (1975) 0.87
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer (2011) 0.87
Statistical design of calibration studies. Am J Clin Nutr (1997) 0.87